Arbutus Biopharma (STU:I9DN) Ending Cash Position : €39.65 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Arbutus Biopharma Ending Cash Position?

Arbutus Biopharma's Ending Cash Position for the quarter that ended in Mar. 2024 was €39.65 Mil.

Arbutus Biopharma's quarterly Ending Cash Position increased from Sep. 2023 (€16.43 Mil) to Dec. 2023 (€24.10 Mil) and increased from Dec. 2023 (€24.10 Mil) to Mar. 2024 (€39.65 Mil).

Arbutus Biopharma's annual Ending Cash Position declined from Dec. 2021 (€96.72 Mil) to Dec. 2022 (€29.05 Mil) and declined from Dec. 2022 (€29.05 Mil) to Dec. 2023 (€24.10 Mil).

Arbutus Biopharma Ending Cash Position Historical Data

The historical data trend for Arbutus Biopharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Ending Cash Position Chart

Arbutus Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

28.62

42.95

96.72

29.05

24.10

Arbutus Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															37.90	25.10	16.43	24.10	39.65

Arbutus Biopharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Arbutus Biopharma's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	28.221	+	-4.118
	=	24.10

Arbutus Biopharma's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	24.182	+	15.471
	=	39.65

Arbutus Biopharma Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma (STU:I9DN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (STU:I9DN) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ABUS:USA

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma (STU:I9DN) Headlines

No Headlines